Jacqueline D. Squire

ORCID: 0000-0002-2600-1306
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunodeficiency and Autoimmune Disorders
  • Immune Cell Function and Interaction
  • Cystic Fibrosis Research Advances
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • NF-κB Signaling Pathways
  • Chronic Lymphocytic Leukemia Research
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Blood disorders and treatments
  • Immune responses and vaccinations
  • Drug-Induced Adverse Reactions
  • Autoimmune and Inflammatory Disorders Research
  • Mast cells and histamine
  • Mycobacterium research and diagnosis
  • Platelet Disorders and Treatments
  • Gastrointestinal disorders and treatments
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Connective tissue disorders research
  • Kawasaki Disease and Coronary Complications
  • Fungal Infections and Studies
  • Inflammasome and immune disorders
  • Autoimmune Bullous Skin Diseases
  • Appendicitis Diagnosis and Management
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Abdominal Trauma and Injuries

Mayo Clinic in Florida
2021-2024

WinnMed
2022-2024

Jacksonville College
2022-2024

Mayo Clinic in Arizona
2023

University of South Florida St. Petersburg
2020

Jacksonville University
2020

University of South Florida
2019-2020

Johns Hopkins All Children's Hospital
2019

Johns Hopkins University
2019

University of Tampa
2018

Safety and efficacy are 2 major drivers for any vaccination strategy have come to the forefront in setting of severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccination. Patients with underlying primary or secondary immunodeficiencies variable response vaccination, but inactivated nonviable vaccines generally considered safe patients immune deficiency.1Sobh A Bonilla FA. Vaccination immunodeficiency disorders.J Allergy Clin Immunol Pract. 2016; 4: 1066-1075Abstract Full Text PDF...

10.1016/j.anai.2021.05.015 article EN other-oa Annals of Allergy Asthma & Immunology 2021-05-19

Background Hereditary alpha tryptasemia (HαT) affects 4-6% of the general population. Inherited as a mendelian dominant, HαT has variable phenotypic expression. Many patients have no obvious symptoms. There is dearth reports possible co-inheritance other genetic abnormalities. Methods We examined records 69 Mayo Clinic with for results any additional studies obtained during routine or focused evaluations. Clinical evaluated baseline tryptase values > 8 ng/mL testing positive TPSAB1...

10.1159/000544704 article EN International Archives of Allergy and Immunology 2025-02-18

Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors immunity should considered. We present three patients after tumor inhibitor use who were found to have immunity.

10.1016/j.ijid.2023.04.007 article EN cc-by-nc-nd International Journal of Infectious Diseases 2023-04-08

Chronic granulomatous disease (CGD) is a primary immune deficiency due to defects in phagocyte respiratory burst leading severe and life-threatening infections. Patients with CGD also suffer from disorders of inflammation dysregulation including colitis lung disease, among others. Additionally, patients may be at increased risk systemic inflammatory such as hemophagocytic lymphohistiocytosis (HLH). The presentation HLH often overlaps symptoms response syndrome (SIRS) or sepsis therefore can...

10.3389/fimmu.2020.581475 article EN cc-by Frontiers in Immunology 2020-12-09

The past 2 years of the COVID-19 pandemic brought with it many unknowns for patients immunodeficiency. Because concern severe infection in those immunocompromise, have been eager effective prevention, vaccination, and treatment strategies. Preexposure prophylaxis provides another means prevention immunocompromise. A combination tixagevimab cilgavimab (Evusheld [AstraZeneca Cambridge, United Kingdom]) was granted emergency use authorization preexposure at end 2021, but questions remained...

10.1016/j.jacig.2023.100081 article EN cc-by-nc-nd Journal of Allergy and Clinical Immunology Global 2023-02-08
Coming Soon ...